ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) is targeting hospitalised patients treated with basic respiratory care, but not mechanical ventilation More: Vicore Pharma bags MHRA nod for COVD-19 trial in record time Source: News
read moreNICE is sharing its work with initiatives such as the WHO’s Evidence Collaborative for COVID-19 More: NICE joins international COVID-19 pandemic response Source: News
read moreIt is expected that the move will allow the EMA to complete its assessment of the drug significantly earlier than with a regular evaluation procedure More: CHMP begins rolling review of Gilead's remdesivir Source: News
read moreThe recommendations bring closer to approval new therapies for asthma, acute myeloid leukaemia, transfusion-dependent anaemia, diabetes, prostate cancer, schizophrenia and multiple sclerosis More: CHMP puts eight new medicines forward for approval Source: News
read moreEven as some pandemic-hit drugmakers lower their revenue expectations for the year—or pull their guidance altogether—Vertex has hit its stride with its Trikafta launch and raised its 2020 sales projections. More: Vertex, even amid pandemic, raises sales projections thanks to gangbusters start for
read moreDozens of drug candidates are being floated as possible therapies for COVID-19, but manufacturing on a mass scale won’t be easy. In a deal with a Bill Gates-funded drug accelerator, Fujifilm Diosynth is hoping to ease some of that production
read more© 1994 - 2026 B.M. Pharmaceuticals